Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Stock Short Interest Declines 77.5%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 184,372 shares, a decrease of 77.5% from the October 15th total of 818,602 shares. Based on an average daily volume of 7,649,526 shares, the days-to-cover ratio is currently 0.0 days. Currently, 6.6% of the company’s shares are short sold.

Alaunos Therapeutics Stock Performance

Shares of TCRT stock opened at $1.60 on Thursday. Alaunos Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $4.50. The stock has a 50 day simple moving average of $1.64 and a two-hundred day simple moving average of $2.29. The company has a market cap of $5.31 million, a P/E ratio of -0.84 and a beta of -1.02.

Alaunos Therapeutics (NASDAQ:TCRT) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc. is a biotechnology company focused on developing genetically engineered T-cell therapies for cancer. The company has concentrated on T-cell receptor (TCR) therapies designed to recognize and attack tumor-specific mutations, with an emphasis on treating solid tumors that can be difficult to address with conventional immunotherapies. The company’s research platform has included the Sleeping Beauty gene-transfer system, a nonviral technology intended to introduce therapeutic T-cell receptors into a patient’s own T cells.